Human genomic pathways to bronchitis virus therapy

November 18, 2015, Agency for Science, Technology and Research (A*STAR), Singapore
Human genomic pathways to bronchitis virus therapy
A 3D rendered illustration of a coronavirus: these are a family of viruses that represent a significant threat to public health. Credit: xrender/iStock/Thinkstock

Viral replication and spread throughout a host organism employs many proteins, but the process is not very well understood. Scientists at A*STAR have led a collaborative study to learn which host factors play a key role in viral replication. The aim was to identify host pathways and processes that operate at various stages of infection by a bronchitis virus that could be targeted to fight viruses.

Led by Frederic Bard at the A*STAR Institute of Molecular and Cell Biology, the researchers infected human with a special bronchitis virus that causes the cell to glow when it replicates. The bronchitis virus belongs to a family, known as coronaviruses, which represent a significant threat to public health: they cause diseases such as severe acute respiratory syndrome (SARS), Middle East respiratory system (MERS), as well as the common cold.

The method by which a virus can infect cells and replicate requires multiple steps. The first step is for the virus to bind to receptors on the membrane, which then folds to enclose the virus in a process called endocytosis. Next the virus is uncoated so that its genome can enter the host cell cytoplasm to allow for to create . Finally the are generated and secreted from the host cell to allow for viral spread.

To determine which factors in the host cell are required for the researchers systematically knocked down the expression of more than 21,000 human genes in the cells. They identified 83 factors in eight different host cellular compartments that are recruited by the virus.

The pertinent pathways include ones that play a role in the movement of vesicles from one part of the cell to another, that splice immature RNAs into more mature forms, and that degrade or refold proteins.

One protein identified by the researchers is called valosin-containing protein (VCP), which they were surprised to find plays a powerful role in viral replication. To determine which part of viral replication it regulates, they looked at which stage the viral assembly got stuck.

They found that knocking down VCP still permitted viral entry into the cell, but caused viruses to get stuck in vesicle structures called early endosomes, rendering the unable to move into the cytoplasm. "Blocking viruses in endosomes could help the cells to degrade them more effectively and the body to get rid of them without much toxicity," explains Bard.

Explore further: Researchers find proteins that shut down HIV-1

More information: Hui Hui Wong et al. Genome-Wide Screen Reveals Valosin-Containing Protein Requirement for Coronavirus Exit from Endosomes, Journal of Virology (2015). DOI: 10.1128/JVI.01360-15

Related Stories

Researchers find proteins that shut down HIV-1

September 30, 2015
A pair of studies by researchers at the University of Massachusetts Medical School, the University of Trento in Italy, and the University of Geneva in Switzerland, point to a promising new anti-retroviral strategy for combating ...

Sendai virus defends against a threat

October 15, 2015
A research group at Hiroshima University demonstrated the mechanism by which the Sendai virus (SeV) escapes the host immune system. The researchers examined the crystal structure of the complex of SeV C protein and transcription ...

Study builds understanding of hepatitis C virus replication

February 23, 2015
Hepatitis C virus infection is a common cause of liver disease and of liver cancer in the United States. Through a new study that explores one aspect of how the virus hijacks host cell machinery to replicate itself, UNC Lineberger ...

Blocking Ebola virus budding by regulating calcium signaling

October 30, 2015
The Ebola virus acts fast. The course of infection, from exposure to recovery, or death, can take as little as two weeks. That may not leave enough time for the immune system to mount an effective response.

Recommended for you

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.